CRISPR at the EU Court

advocate-general-opinionAgbiotech supporters and opponents have been waiting for months for the opinion of the Advocate General of the European Court of Justice, hoping that it would settle the fateful question: do edited plants follow the same legislation as GMOs? The answer, however, does not appear to be conclusive and has been variously interpreted. Nature, The Scientist, and The Guardian are cautiously optimistic, but this Euractiv article is even more interesting. Uncertainty is the prevailing mood in this field. Continue reading

CRISPR plants are coming, and USDA is fine

SoybeansThe US Department of Agriculture has given the green light to five CRISPR-edited plants in the last couple of years. See the table below, published by Nature Biotechnology this month. CRISPR is set to make its commercial debut in fields in 2020, with DuPont Pioneer’s waxy corn, and hopes are high that gene editing will give us the chance of rewriting the GMO debate. Continue reading

2018: Happy New Edit!

This slideshow requires JavaScript.

2017 ends with over 3,000 CRISPR papers indexed by PubMed and 6,810,000 Google’s search results. There is no doubt that 2018 is going to be hot, with the brand new CRISPR Journal launching in 2018 and leading scientists convening at a super CRISPR meeting in Lithuania next June. Clinical trials for genetic diseases such as beta-thalassemia and Leber congenital amaurosis are expected to start, and a forthcoming European Court verdict could be a turning point for the future of edited crops. Happy new year and happy new edit then, surprisingly surprising surprises ahead!

Epigenetic editing hits hat-trick

editing epigenetico Cell

Reversing three genetic diseases in the animal model without even changing a single DNA letter. A Salk Institute team did it by bringing together two of biomedicine’s hottest trends. One is the CRISPR technique, which edits target genes through a programmable molecular machine named Cas9. The other is epigenetics, i.e., the study of chemical modifications that switch genes on and off without altering their sequence. It’s called epigenetic editing, because corrections are precise as in manuscript revision and occur at a level that is over (epi- in Greek) genetics. Continue reading

Gene drives: the experiment goes social

harvard-mag-pete-ryanChoose a word to fill the gap in the sentence. “Gene drives are an ambitious experiment in …”. Genetics? Ecology? Evolution? Obviously, gene drives are all this and more. They may also represent a significant social experiment in risk communication, public engagement, participatory processes. Potential applications of this technology include controlling the transmission of vector-borne diseases and eliminating invasive species from sensitive ecosystems. We do not yet know if these genetic elements, designed to foster the preferential inheritance of a gene of interest with CRISPR’s help, will work in field trials as hoped. To find out, a green light to test this technology out of the labs will have to be negotiated with the public, stakeholders, regulators, and governments of affected countries. A first step in this direction was taken last week with the commitment to respect shared guiding principles in gene drive research and communication published in Science by the technology main sponsors and supporters. Signatory organizations are scattered around the world, from the US to India, with the Bill & Melinda Gates Foundation at the forefront with its Target Malaria project. Continue reading